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Carolyn W. Taylor4, Sarah C. Darby4, Michael Hauptmann1, Caroline M. Seynaeve2, Margreet H. A. Baaijens6, Gabe S. Sonke7,
Emiel J. T. Rutgers8, Nicola S. Russell9, Berthe M. P. Aleman9 and Flora E. van Leeuwen1
BACKGROUND: Improved breast cancer (BC) survival and evidence showing beneﬁcial effects of internal mammary chain (IMC)
irradiation underscore the importance of studying late cardiovascular effects of BC treatment.
METHODS: We assessed cardiovascular disease (CVD) incidence in 14,645 Dutch BC patients aged <62 years, treated during
1970–2009. Analyses included proportional hazards models and general population comparisons.
RESULTS: CVD rate-ratio for left-versus-right breast irradiation without IMC was 1.11 (95% CI 0.93–1.32). Compared to right-sided
breast irradiation only, IMC irradiation (interquartile range mean heart doses 9–17 Gy) was associated with increases in CVD rate
overall, ischaemic heart disease (IHD), heart failure (HF) and valvular heart disease (hazard ratios (HRs): 1.6–2.4). IHD risk remained
increased until at least 20 years after treatment. Anthracycline-based chemotherapy was associated with an increased HF rate
(HR= 4.18, 95% CI 3.07–5.69), emerging <5 years and remaining increased at least 10–15 years after treatment. IMC irradiation
combined with anthracycline-based chemotherapy was associated with substantially increased HF rate (HR= 9.23 95% CI
6.01–14.18), compared to neither IMC irradiation nor anthracycline-based chemotherapy.
CONCLUSIONS: Women treated with anthracycline-based chemotherapy and IMC irradiation (in an older era) with considerable
mean heart dose exposure have substantially increased incidence of several CVDs. Screening may be appropriate for some BC
patient groups.
British Journal of Cancer (2018) 119:408–418; https://doi.org/10.1038/s41416-018-0159-x
INTRODUCTION
Breast cancer (BC) survival has improved substantially in recent
decades due to earlier diagnosis and treatment advances.1–5 At
present, both radiation therapy (RT) and anthracycline-based
chemotherapy are commonly used. They cure many women of
their cancer but both treatments have been associated with
increased risks of cardiovascular disease (CVD).6,7 Radiation-related
CVDs include ischaemic heart disease (IHD) and valvular heart
disease (VHD), with evidence for dose-dependency.8–10 Previously,
RT-related CVDs were thought not to emerge until 10 years after
exposure.11–15 Recently, however, increased risks have been
observed within 5 years of exposure.8,16 Anthracycline-based
chemotherapy is associated with an increased, dose-dependent
risk of cardiomyopathy (CMP) and heart failure (HF).17–19 However,
the reported cumulative HF incidence after anthracycline-based
chemotherapy varies.20–23
Since the 1970s, thousands of women in the Netherlands have
been treated with internal mammary chain (IMC) irradiation using
techniques that deliver substantial radiation doses to the heart.
Since the 1990s, many women in the Netherlands have also
received anthracycline-based chemotherapy. The absolute heart
disease risks for women treated in the past are currently unclear,
and it is not known which women might beneﬁt from surveillance
for heart disease.
Recent randomised trials have reported a BC-speciﬁc survival
beneﬁt after nodal irradiation, including IMC irradiation.24,25 This
has re-opened the debate on the role of IMC irradiation in BC
treatment.26 Women given IMC radiotherapy today may still
receive around 8 Gy,27–30 but some cancer centres achieve much
lower heart doses.28,29,31 Many of these women also receive
anthracycline-based chemotherapy. Identifying interactions
between RT and anthracycline-based chemotherapy or
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established cardiovascular risk factors8,11,32 is therefore relevant to
women treated today.
Here we report the separate and combined effects of various
radiation ﬁelds, chemotherapy types and established cardiovas-
cular risk factors on the long-term risks of IHD, VHD and HF in a
large cohort of BC patients aged <62 years at diagnosis.
METHODS
Data collection procedures
Female BC patients (stages I–IIIA or ductal carcinoma in situ [DCIS])
were selected from the hospital-based registries of the Nether-
lands Cancer Institute, Amsterdam or the Erasmus MC - Cancer
Institute, Rotterdam, the Netherlands. All patients were diagnosed
during 1970–2009 and before the age of 62 years. Data collection
procedures have been published previously.11 In brief, patient and
tumour characteristics, BC treatments (also locoregional recur-
rences and subsequent BCs) and CVD events were collected from
registries and patient records. Patients were scored positive for
hypertension, diabetes mellitus or hypercholesterolaemia if they
received treatment for these conditions. Supplementary methods I
shows detailed data collection procedures and patient eligibility
criteria.
To complete information on CVD incidence, cardiovascular risk
factors and causes of death, questionnaires were sent to general
practitioners (GPs)i and, if applicable, cardiologists of all patients.
(iIn the Netherlands, all residents are expected to have a primary
care physician. Medical correspondence from attending physicians
is sent to the primary care physician. Such records are preserved
by the primary care physicians throughout a patient’s life and for
at least 15 years after a patient’s death). Date of death was
acquired through the population-based municipal personal
records database.
In the current study, women treated with trastuzumab or
taxanes (with or without anthracycline-based chemotherapy) for
their primary BC (n= 979) were excluded, since follow-up was
short and the numbers of events were too small to examine the
effects of these treatments on CVD risks. The total analytic cohort
comprised 14,645 patients.
Treatment
A detailed description of the treatment modalities used in our
cohort from 1970 to 1986 has been published previously.11 During
the 1970s, standard treatment for stage I–IIIa BCs consisted of
mastectomy, with/without RT. In 1975, CMF (cyclophosphamide,
methotrexate and ﬂuorouracil) chemotherapy was introduced for
premenopausal lymph node-positive patients. Breast-conserving
surgery followed by whole breast irradiation was introduced
in 1980. For women who underwent mastectomy, chest
wall irradiation was indicated following incomplete resection
or for extensive locoregional tumours. Regional nodal
irradiation, including IMC irradiation, was used for women
with positive axillary nodes and, in some cases, medial
tumours. From the 1990s, anthracycline-based chemotherapy
was used for most premenopausal, and later also for postmeno-
pausal, lymph-node positive patients and for lymph-node
negative patients with unfavourable tumour characteristics. Most
common anthracycline dose was four times 60 mg/m2 (doxor-
ubicin equivalent) during the study period. DCIS was treated with
either wide local excision followed by whole-breast RT or with
mastectomy.
In previous decades, IMC irradiation usually consisted of direct
photon beams, sometimes combined with electron beams, giving
a total target dose of 36–54 Gy in 12–26 fractions. In the most
recent treatment period, IMC irradiation consisting of a combina-
tion of oblique photon and electron beams giving a total target
dose of 50 Gy (25 fractions) resulting in lower exposure of the
heart was introduced.33 Chest wall irradiation usually consisted of
a direct electron beam giving a total target dose of 35–46 Gy
(15–23 fractions). Whole breast irradiation usually consisted of
tangential photon beams giving a total target dose of 44–52 Gy
(22–26 fractions); most women also received a boost dose to the
tumour bed.
Dosimetry
Dosimetry was performed to provide an indication of the typical
level of cardiac exposure for women who received RT to different
regions, according to laterality and IMC irradiation, during
different time periods. Detailed information on the RT received
was available for a sample of 683 women in the study cohort. Over
90% of these women were treated before the era of RT computed
tomographic (CT) planning. Typical mean heart doses were
estimated by reconstructing 44 different regimens on a “typical
CT scan” (Supplementary methods II: Dosimetry). Dose distribu-
tions were generated for cobalt, electron and megavoltage beams
using modern 3-dimensional CT treatment planning (Varian
EclipseTM Treatment Planning System [TPS] version 10.0.39
[Varian Medical Systems, Palo Alto, USA]) and for orthovoltage
ﬁelds using manual planning. A typical mean heart dose was
allocated to each woman according to her regimen and total dose.
Women were then categorised according to laterality and whether
they received IMC irradiation. Within these categories, the typical
doses were averaged. Given the large total number of women in
the cohort, individual dosimetry was not undertaken and there-
fore no dose–response analyses have been performed.
Statistical analysis
BC treatments received throughout follow-up (including treat-
ment for contralateral BCs and locoregional recurrences) were
classiﬁed time-varyingly. Chemotherapy regimens were cate-
gorised as CMF-like or anthracycline-based regimens. Differences
in the likely radiation exposure of the heart were accounted for by
considering laterality and radiation ﬁelds (breast, chest wall, IMC).
Because collection of CVD incidence for patients treated during
1970–1986 was restricted to 10-year survivors,11 time-at-risk
started 10 years after BC diagnosis for patients diagnosed ≤1986
and 1 year after BC diagnosis for patients diagnosed >1986. Time-
at-risk ended at date of event of interest, death, emigration,
distant metastasis or date of last information, whichever came
ﬁrst.
General population comparisons. The incidence rate of myocar-
dial infarction (MI) and HF (comprising congestive HF and CMP) in
the cohort was compared with age-, sex- and calendar period-
speciﬁc CVD incidence rates for the Dutch population.34,35 No
comparable reference rates were available for VHD and angina
pectoris (AP). We calculated standardised incidence ratios (SIRs)
and absolute excess risks and estimated 95% conﬁdence intervals
(CIs).36
Within-cohort comparisons. We assessed the association between
treatments and CVD risk using proportional hazard models. A
cardiovascular event was deﬁned as a CVD diagnosis or death due
to CVD. We estimated risks for any CVD (ICD-10 I20–52) and
separately for IHD (MI and AP), VHD and HF. When analysing a
speciﬁc CVD, the presence of any other CVD was treated as a time-
dependent covariate. Additionally, age at BC, CVD history, risk
factors at BC diagnosis (dichotomised into yes/no) and smoking
were included in the models as main effects. Treatment-speciﬁc
cumulative CVD incidence was estimated in patients above and
below 50 years at BC diagnosis (to avoid mixing different age/
treatment distributions), in the presence of death from causes
other than CVD as a competing risk.37 Model assumptions were
veriﬁed using residual-based methods. Because the proportional
hazard assumption did not hold for the IHD rate after IMC and
chest wall irradiation, analyses are presented separately for <10
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Table 1. Characteristics of hospital-based cohort of 14,645 breast cancer patients by year of breast cancer diagnosis
Year of breast cancer diagnosis
Total 1970–1986 1987–1999 2000–2009
Characteristic No. % No. % No. % No. %
Total no. of patients 14,645 100 3571 100 6626 100 4448 100
Age at diagnosis (years)
Median (IQR) 47 (42–52) 47 (42–53) 46 (41–50) 51 (45–56)
<35 yearsa 1010 6.9 236 6.6 562 8.5 212 4.8
35–40 years 1568 10.7 433 12.1 813 12.3 322 .2
40–49 years 6586 45.0 1600 44.8 3486 52.6 1500 33.7
50–61 years 5481 37.4 1302 36.5 1765 26.6 2414 54.3
Stage
Ductal carcinoma in situ 929 6.3 40 1.1 318 4.8 571 12.8
I 4436 30.3 327 9.2 2168 32.7 1941 43.6
II 5251 35.9 433 12.1 3427 51.7 1391 31.3
IIIa 497 24.1 4 0.1 256 3.9 308 5.3
Unknown 3532 3.4 2767 77.5 457 6.9 237 6.9
Type of surgeryb
Mastectomy 8186 55.9 1139 31.9 4178 63.1 2869 64.5
Wide local excision 5127 35.0 2423 67.9 1639 24.7 1065 23.9
Type of surgery unknown 1332 9.1 9 0.3 809 12.2 514 11.6
Radiation therapy and chemotherapyb
None 1663 11.4 439 12.3 578 8.7 646 14.5
Radiation therapy alone 8137 55.6 2513 70.4 3502 52.9 2122 47.7
Chemotherapy alone 406 2.8 19 0.5 216 3.3 171 3.8
Radiation therapy and chemotherapy 4439 30.3 600 16.8 2330 35.2 1509 33.9
Radiation ﬁeldsb
No radiation therapy 2069 14.2 458 12.8 794 12.0 817 18.4
Breast, no IMC 6301 43.0 621 17.4 3285 49.6 2395 53.8
Typical mean heart dose left/right (Gy) 4.8/0.6 Gy 4.3/0.6 Gy 4.8/0.7 Gy 1.5/0.3 Gy
Chest wall, no IMC 796 5.4 337 9.4 382 5.8 77 1.7
Typical mean heart dose left/right (Gy) 5.8/2.8 Gy 4.0/2.8 Gy 6.3/2.8 Gy 1.5/0.3
IMC, no chest wall or breast 2269 15.5 1164 32.6 850 12.8 255 5.7
Typical mean heart dose left/right (Gy) 14.7/8.9 Gy 12.2/8.9 Gy 16.5/9.9 Gy 16.1/9.4 Gy
IMC and breast 1429 9.8 475 13.3 679 10.3 275 6.2
Typical mean heart dose left/right (Gy) 16.6/13.4 Gy 16.6/15.3 Gy 21.8/13.4 Gy 9.1/9.2 Gy
IMC and chest wall 806 5.5 430 12.0 226 3.4 150 3.4
Typical mean heart dose left/right (Gy) 16.1/10.1 Gy 14.8/12.6 Gy 16.4/10.5 Gy 16.1/1.7 Gy
Unknown 975 6.7 86 2.4 410 6.2 479 10.8
Chemotherapy regimenb
No 9800 66.9 2952 82.7 4080 61.6 2768 62.2
CMF-like regimens 2029 13.9 619 17.4 1422 21.5 0 0
Anthracycline-based regimensc 2816 19.2 0 0 1124 17.0 1680 37.8
Endocrine therapyb
No 12,205 83.3 3503 98.1 6.043 91.2 2659 59.8
Yes 2440 16.7 68 1.9 583 8.8 1789 40.2
Cardiovascular risk factors at breast cancer diagnosisd
None known 10,908 74.5 1875 52.5 5132 77.5 3901 87.7
Hypertension, hypercholesterolemia or diabetes mellitus 671 4.6 355 9.9 186 2.8 130 2.9
Smokinge 2966 20.3 1265 35.4 1326 20.0 375 8.4
History of cardiovascular disease 484 3.3 315 8.8 82 1.3 97 2.0
Follow-up time (years)
Median (IQR) 14 (9–20) 23 (17–28) 15 (9–19) 9 (6–11)
1–4 years 1297 9.8 0 0 917 15.1 380 10.6
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and ≥10 years after treatment.
We evaluated whether the observed data were consistent with
an additive or a multiplicative model for the joint effect of two risk
factors A and B by likelihood ratio tests of γ= 0 in models HR
(A,B)= 1+ β1A+ β2B+ γA×B and HR(A,B)= exp(α+ β1A+ β2B+
γA×B).38 Analyses were performed using Stata/SE 13.0 (StataCorp
LP, College Station, TX) and EPICURE 1.8 (Hiro Soft International
Inc, Seattle, WA). The study was approved by the review board of
the Netherlands Cancer Institute.
RESULTS
The median follow-up duration of our cohort (n= 14,645) was 14
years, with 3486 patients followed ≥20 years. Median age at BC
diagnosis was 47 years. Eighty six percent of patients received RT,
of whom 36% had IMC irradiation. One third of the patients
received chemotherapy (58% anthracycline-based). Few patients
were treated for cardiovascular risk factors at BC diagnosis (4.6%),
but >20% were current or past smokers (Table 1). A statistically
signiﬁcant but small difference in CVD history was observed
between left- and right-sided BC patients (left-sided: 3.6%, right-
sided: 3.0%). Other characteristics, including treatments, did not
differ signiﬁcantly by laterality (data not shown). BC treatment
(including the receipt of IMC irradiation and anthracycline-based
chemotherapy) was not associated with socioeconomic status,
cardiovascular history at BC diagnosis or cardiovascular risk
factors. (Supplementary table 7)
General population comparisons
Compared to the general population, our cohort had a higher MI
rate (SIR= 1.4 95% CI 1.3–1.6), whereas the HF rate was not
increased overall (SIR= 1.0 95% CI 0.9–1.1) (Table 2). While for HF
the highest SIRs were seen for young ages at BC diagnosis, MI
rates were increased only for older ages at diagnosis (Table 2).
Subdividing the entire cohort by follow-up duration and
treatment period, an increased HF rate was observed 1–9 years
after treatment in patients treated ≥1987 (SIR= 1.4 95% CI 1.1–1.9
for 1987–1999 and 1.5 95% CI 1.0–2.0 for 2000–2009). In contrast,
the increases in the MI rate were greatest in the longest follow-up
intervals.
Among patients treated with neither RT nor chemotherapy, the
MI rate was not increased (SIR= 0.8 95% CI 0.5–1.1) and the HF
rate was decreased (SIR= 0.5 95% CI 0.4–0.8) compared with the
general population. Increased MI rates were observed after RT (e.g.
SIR= 1.5 95% CI 1.4–1.7 for patients treated with RT and without
chemotherapy), while HF rates were increased after anthracycline-
based chemotherapy (SIR= 4.6 95% CI 3.7–5.7).
Within-cohort comparisons
For women treated with RT, the lowest typical mean heart doses
were for those who received right-sided breast irradiation without
IMC (0.6 Gy, interquartile range (IQR) 0.3–0.7) (Table 1, Supple-
mentary table 1). Compared to this group, women who received
IMC irradiation (either left- or right-sided, average of mean heart
doses for typical IMC irradiation 12.2 Gy, IQR 8.7–16.5) had
signiﬁcantly increased rates of all four cardiovascular outcomes:
any CVD (hazard ratio (HR)= 1.56 95% CI 1.35–1.84), IHD (HR=
2.36 95% CI 1.74–3.22), VHD (HR= 1.63 95% CI 1.18–2.24) and HF
(HR= 1.82 95% CI 1.27–2.63, based on inclusion of multiple CVDs
per woman) (Summary model, Table 3). Increases were observed
after both left- and right-sided IMC (Table 3) and with/without
additional breast or chest wall radiation (Supplementary table 2).
Increased rates of any CVD and of IHD were also seen after left
chest wall irradiation (average of typical mean heart doses 5.8 Gy,
IQR 3.8–5.3) when compared to right breast irradiation (HRs were
1.83 95% CI 1.39–2.40 and 2.57 95% CI 1.61–4.11, respectively). In
the entire cohort, no signiﬁcant increases were observed in
women with left breast irradiation (average of mean heart doses
4.7 Gy, IQR 1.5–4.8) compared to those treated with right breast
irradiation (HR for IHD 1.38 95% CI 0.96–1.99, Supplementary
table 2); yet, for women treated at age ≤50 years an increased rate
of IHD was observed (HR= 1.70 95% CI 1.03–2.80) (Supplementary
table 3). Additional analyses considered just the ﬁrst cardiovas-
cular event and found the following (very similar) HRs for women
who received IMC irradiation compared with women who
received right-sided breast irradiation without IMC: any CVD (HR
= 1.49 95% CI 1.25–1.77), IHD (HR= 2.51 95% CI 1.70–3.72), VHD
(HR= 1.57 95% CI 1.02–2.44) and HF (HR= 1.71 95% CI 0.99–2.94)
(Supplementary table 4).
Women treated with anthracycline-based chemotherapy had
increased rates of VHD (HR= 1.75 95% CI 1.16–2.65) and HF
(HR= 4.32 95% CI 3.07–6.07) compared to no chemotherapy
(Table 3, based on inclusion of multiple CVDs per woman). When
just the ﬁrst cardiovascular diagnosis was considered, the increase
in HF was slightly reduced (HR= 3.93 95% CI 2.49–6.22)
(Supplementary table 4). When including VHD events diagnosed
on the same day as IHD/HF, the anthracycline-based chemother-
apy-associated risk of VHD was still increased (HR= 1.70 95% CI
1.09–2.65), but when excluding such VHD events the HR dropped
to 1.11 (95% CI 0.62–2.00). Additional stratiﬁcation by treatment
Table 1 continued
Year of breast cancer diagnosis
Total 1970–1986 1987–1999 2000–2009
Characteristic No. % No. % No. % No. %
5–9 years 2604 19.7 0 0 723 11.9 1881 52.6
10–19 years 5816 44.0 1344 37.7 3154 52.0 1318 36.8
20–29 years 2979 22.5 1702 47.7 1277 21.1 0 0
≥30 years 523 4.0 523 14.7 0 0 0 0
Vital status
Alive 10,064 68.7 1889 52.9 4240 64.0 3935 88.5
Deceased 4580 31.3 1682 47.1 2385 36.0 513 11.5
IQR interquartile range, IMC internal mammary chain. aMedian age for patients aged <35 years at diagnosis was 32 years, with an interquartile range of 30–34
years. bMutually exclusive treatment groups, taking into account primary treatment only. cIncluding either epirubicin or doxorubicin. d335 patients had more
than one of the mentioned cardiovascular risk factors at breast cancer diagnosis and these patients are listed more than once. The most frequent
combinations involved current or previous smoking. eSmoking deﬁned as quit shortly before breast cancer diagnosis, smoker at breast cancer diagnosis or
smoker during follow-up. 17.5 % of the cohort had never smoked. Smoking information was missing for 62.3% of the cohort
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period did not affect the estimates (results not shown). No
increased CVD rates were observed comparing patients treated
with endocrine therapy to no endocrine therapy.
The joint effects of IMC irradiation, anthracycline-based
chemotherapy, cardiovascular risk factors at BC diagnosis and
smoking were compatible with either an additive or a multi-
plicative relation for all CVDs (Supplementary table 6). For
HF, however, the combined effect of IMC irradiation and
anthracycline-based chemotherapy seemed more than additive
(p= 0.06). A more than nine-fold increase was observed among
patients treated with both IMC irradiation and anthracycline-
based chemotherapy (HR= 9.23 95% CI 6.01–14.18), whereas
the separate HRs were 2.14 (95% CI 1.55–2.96) and 5.10 (95% CI
3.12–8.34), respectively, all compared to either IMC or
anthracycline-based chemotherapy (Table 3).
When analysing IHD rates by time since treatment, no
signiﬁcant increases were seen in the ﬁrst 10 years (Fig. 1,
Supplementary table 5). IMC irradiation during 1970–1986 or
Table 2. Comparison of myocardial infarction and heart failure rates with the general population
Myocardial infarctiona Heart failurea
Observed SIR 95% CI AER Observed SIR 95% CI AER
Total 394 1.4 1.3–1.6 8 396 1.0 0.9–1.1 0
Age at breast cancer diagnosis (years)
<35 5 0.9 0.3–2.1 0 12 2.7 1.4–4.7 7
35–40 17 1.1 0.7–1.8 1 20 1.4 0.9–2.2 4
40–49 180 1.5 1.3–1.7 8 179 1.1 1.0–1.3 3
50–61 192 1.4 1.2–1.6 12 185 0.8 0.7–1.0 −8
Calendar period of breast cancer diagnosis and follow-up interval
1970–1986
10–19 years 128 1.3 1.1–1.5 21 91 0.8 0.7–1.0 −16
20+ years 120 2.1 1.7–2.5 210 127 0.9 0.7–1.0 −63
1987–1999
1–9 years 41 0.7 0.5–1.0 -6 57 1.4 1.1–1.9 8
10–19 years 54 1.7 1.3–2.2 15 64 1.1 0.8–1.4 3
20+ years 8 1.7 0.7–3.4 24 9 0.8 0.4–1.5 −17
2000–2009
1–9 years 26 1.5 1.0–2.2 7 36 1.5 1.0–2.0 9
10+ years 6 2.0 0.7–4.3 23 12 2.6 1.3–4.5 58
Radiation therapy and chemotherapy
None 29 0.8 0.5–1.1 −5 33 0.5 0.4–0.8 −16
Radiation therapy alone 264 1.5 1.4–1.7 12 233 0.9 0.7–1.0 −5
Chemotherapy alone 6 2.6 0.9–5.5 13 8 2.7 1.2–5.3 16
Radiation therapy and chemotherapy 75 1.7 1.4–2.2 9 122 2.1 1.7–2.5 16
Radiation ﬁeldsb
Breast (no IMC) 87 1.2 0.9–1.4 2 81 0.8 0.6–1.0 −3
Chest wall (no IMC) 34 1.5 1.0–2.0 14 42 1.0 0.7–1.3 −1
IMC 203 1.9 1.6–2.1 23 205 1.2 1.0–1.4 6
Chemotherapy regimens
CMF-like regimens 59 1.7 1.3–2.2 11 44 1.0 0.8–1.4 0
Anthracycline-based regimensc 22 1.5 0.9–2.2 3 86 4.6 3.7–5.7 33
Cardiovascular risk factor at BC diagnosisd
None known 342 1.3 1.2–1.5 6 347 1.0 0.9–1.1 −1
At least one 52 2.3 1.7–3.0 42 49 1.3 1.0–1.8 17
Smoking
Never 110 1.1 0.9–1.3 3 115 0.8 0.6–0.9 −10
Currently or previous 174 2.3 2.0–2.7 28 141 1.4 1.2–1.6 11
Unknown 110 1.0 0.8–1.2 0 140 0.9 0.8–1.1 −1
SIR standardised incidence ratio, CI conﬁdence interval, AER absolute excess risk, IMC internal mammary chain. aExpected numbers were calculated using age-,
sex- and calendar period-speciﬁc CVD incidence rates for the Dutch population. Myocardial infarction and heart failure incidence data from the Continuous
Morbidity Registration Nijmegen of General Practices were used as reference rates for the years 1971–1999 and from the Netherlands Institute for Health
Services Research Primary Care Database from 2000 onwards. Myocardial infarction included diagnoses I21–22 International Classiﬁcation of Diseases, 10th
revision. Heart failure included both cardiomyopathy and congestive heart failure; diagnoses I42 and I50 International Classiﬁcation of Diseases, 10th revision.
These were the only two cardiovascular diseases for which general population data were available. Just as in the general population registries, each individual
patient in our cohort could have had a diagnosis of both myocardial infarction and heart failure. bMutually exclusive treatment categories. cIncluding either
epirubicin or doxorubicin. dHypertension, hypercholesterolaemia or diabetes mellitus
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1987–1999 was associated with increased IHD rates ≥10 years
after treatment (Fig. 1, Table 4); the HR for 0–9 years after IMC
irradiation compared to breast irradiation only during 1987–1999
was 1.32 (95% CI 0.74–2.37), while for 10+ years the HRs were 1.64
(95% CI 1.19–2.25) and 1.72 (95% CI 1.17–2.53) for 1970–1986 and
1987–1999, respectively. In the period 2000–2009, numbers were
too small to detect or reject a risk increase for either 0–9 or ≥10
years after IMC irradiation (Table 4). HF rates after anthracycline-
based chemotherapy were increased compared to no chemother-
apy during the period 1–4 years after diagnosis (HR= 6.80 95% CI
2.75–16.82) and remained increased until at least 10–15 years after
treatment (HR= 4.03 95% CI 2.70–6.00).
Among women diagnosed before age 50 years during
1987–1999, the cumulative incidence of IHD twenty years after
BC treatment was 11.3% (95% CI 6.8–17.1) for those who received
IMC irradiation and had a cardiovascular risk factor (including
smoking) at diagnosis compared to 6.4% (95% CI 4.5–8.7) for those
who had a cardiovascular risk factor but did not receive IMC
irradiation (Fig. 2). For VHD and HF, the cumulative 20-year
incidences were also considerably higher for women who received
IMC radiation and had a cardiovascular risk factor compared with
those who had a cardiovascular risk factor but no IMC radiation.
Results for age 50+ years are in Supplementary Figure 1.
Cumulative incidences of IHD, VHD and HF by anthracycline-
based treatment and IMC irradiation for women aged ≤50 years
are given in Supplementary Figure 2.
Women treated more recently (1990–2006) had a lower
cumulative MI risk than women treated in earlier years
(1970–1989) (Supplementary Figure 3). In addition, the absolute
increase in cumulative MI risk compared to the population-
expected risk was notably smaller for those treated during
1990–2006 than for those treated before 1990. When compared
with women receiving right breast RT only, the HR for all other RT
regimens was 2.82-fold (95% CI 1.48–5.37) for the period
1980–1989 and 1.84 (95% CI 0.83–4.05) for the period
1990–2006 (10-year survivors only; pdifference= 0.41).
DISCUSSION
Our study shows that, in women treated for BC in the Netherlands
between 1970 and 2009, IMC irradiation was associated with an
increased incidence of IHD, VHD and HF. Risk increases were seen
not only after left-sided but also after right-sided IMC irradiation,
and importantly, the proportional increase in the risk of IHD was
greatest in the period >20 years after treatment. Anthracycline-
based chemotherapy was associated with increased incidence of
HF. The combination of IMC irradiation and anthracycline-based
chemotherapy was associated with a nine-fold increased inci-
dence of HF relative to patients who received only breast RT and
no anthracycline-based chemotherapy.
Anthracycline-based chemotherapy (received by women in our
cohort after 1990) was associated with increased HF incidence up
to 15 years after treatment; there was insufﬁcient follow-up to
assess risk beyond this. Our estimate of the proportional increase
in the rate (HR= 4.32) is somewhat higher than previously
reported in population-based studies.21,39,40 A possible explana-
tion is the young age of the women in our cohort, as we observed
an even larger increases in patients treated ≤50 years (HR= 5.23
95% CI 3.41–8.01).
The increased VHD rate after anthracycline-based chemother-
apy when multiple CVD diagnoses per woman are considered is a
new ﬁnding in BC patients. Our detailed analysis, however,
excluding VHD events diagnosed at the time of HF/IHD diagnosis
suggests that the anthracycline-based chemotherapy-associated
VHD risk in this cohort may be caused by anthracycline-based
chemotherapy-related HF, rather than a direct effect of
anthracycline-based chemotherapy. An anthracycline-related
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Left-sided breast alone (no IMC) vs.
right-sided breast alone (no IMC)
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Fig. 1 Within cohort comparison of ischemic heart disease rates by time since treatment and radiation therapy in patients diagnosed during
1970-1999. The analyses shown in this ﬁgure include all diagnoses of ischemic heart disease, e.g. including patients diagnosed with valvular
heart disease or heart failure prior to ischemic heart disease. For women diagnosed with breast cancer during 1970-86, data on cardiovascular
disease were available only for the period 10+years after treatment. IMC, internal mammary chain.Cox proportional hazard model including
the following variables: radiation ﬁelds (right-), age at breast cancer treatment (<40, 40-49, 50-61 years), chemotherapy (none, CMF-like,
anthracycline-based chemotherapy), cardiovascular risk factor at breast cancer diagnosis yes/no (hypertension, hypercholesterolemia, or
diabetes), smoking (ever, never, or unknown), and other cardiovascular diseases diagnoses (time-dependent).In the period 2000-2009 follow-
up duration was too short for reliable estimates (see Table 4)
Table 4. Within-cohort comparison of ischaemic heart disease ratios for different radiation ﬁelds by time since treatment and treatment period
Treatment period Time since treatment
Radiation ﬁelda 0–9 years 10–19 years 20+ years
n/N HR (95% CI) n/N HR (95% CI) n/N HR (95% CI)
1970–1986
Breast only (no IMC) 0/0 — 44/1162 1.00 Ref. 11/402 1.00 Ref.
IMCb 0/0 — 318/3899 1.35 0.93–1.96 144/1455 2.51 1.35–4.67
1987–1999
Breast only (no IMC) 37/3345 1.00 Ref. 66/3432 1.00 Ref. 10/784 1.00 Ref.
IMCb 20/1524 1.32 0.74–2.37 48/1340 1.68 1.09–2.57 9/261 2.11 0.85–5.25
2000-2009
Breast only (no IMC) 34/2,028 1.00 Ref. 8/686 1.00 Ref. 0/0 —
IMCb 5/544 0.62 0.23–1.62 4/290 0.90 0.26–3.05 0/0 —
n/N number of events/number at risk, HR hazard ratio, CI conﬁdence interval, IMC internal mammary chain, Ref. reference category. aPatients were time-
dependently categorised based on the treatment they received throughout follow-up into irradiation of the breast without internal mammary chain
irradiation (either left or right breast), internal mammary chain irradiation (left- of right-sided) with or without radiation of additional ﬁelds and no/other
radiation ﬁelds (estimates not shown). bIrradiation of the left- or right-sided internal mammary chain, with or without additional irradiation of the breast or
chest wall
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increase in the diagnosis of VHD as a ﬁrst CVD event has
previously been observed in Hodgkin lymphoma patients.41,42
In a recent case–control study, the risk of a major coronary
event increased by 7.4%/Gy mean heart dose.8 Although not
statistically signiﬁcant, our HR of 1.38 for left breast (~5 Gy typical
mean heart dose) versus right breast RT (~0.6 Gy typical mean
heart dose) is consistent with these results. In our large,
population-based cohort of early BC patients,43 we studied
hospitalisation for CVD and also found an increased rate of IHD
comparing left- versus right-sided breast irradiation (without IMC
irradiation) (HR= 1.24 95% CI 1.01–1.52). These ﬁndings, together
with the increased rate we observed in patients treated at age ≤50
years in the current study, suggest that left breast irradiation does
slightly increase IHD risk. Also in line with Darby and colleagues’
results are our IHD HRs of 1.77–2.78 for women who received
typical heart doses of ~9–15 Gy from IMC RT compared with
women with right breast RT. The effect of cardiovascular risk
factors on radiation-related cardiac risk in the two studies is also
consistent. In both studies, cardiovascular risk factors prior to RT
did not signiﬁcantly increase relative risk of radiation-related CVD
but did increase the absolute risk due to RT. Our study included
patients up to the age of 61 years at BC diagnosis. Older patients
generally have more cardiovascular risk factors. Hence, the
absolute risks of treatment-related CVD may be higher in older
patients. Additionally, the presence of cardiovascular risk factors
might inﬂuence the onset of treatment-related CVD. Future
studies should focus also on older BC patients and the onset of
the increased CVD rates among these older patients.
Our results are relevant to a large number of BC survivors
treated with older IMC regimens, who may remain at an elevated
CVD risk for an extensive period. Follow-up in our study was too
short to detect or reject an IHD risk increase associated with IMC
irradiation during 2000–2009. Recent studies showing improved
BC survival after IMC irradiation24,25,44 still have insufﬁcient follow-
up (≤10 years) to detect an increased CVD risk which, as we report,
continues into the third decade after treatment. For women who
receive BC treatment today, the predicted absolute risks of IMC RT
are expected to be substantially lower than for the women in our
study. This is partly because the IHD risk in the general population
has decreased substantially since the 1970s (Supplemental
Figure 3). A recent systematic review of heart dose estimates
from BC RT during 2003–2013 showed that heart dose from IMC
regimens varied according to technique and was typically ~8 Gy in
left-sided RT27, which is lower than the average of ~13 Gy in our
study. Modern radiotherapy techniques, including intensity-
modulated radiotherapy and deep-inspirational breath hold, can
deliver mean heart doses of <4 Gy even for IMC radiotherapy in
left-sided tumours and their use is strongly recommended.
Our results suggest that the combined effects of radiation and
anthracycline-based chemotherapy may be greater than their
individual effects on the heart. This ﬁnding needs conﬁrmation as
in several countries guidelines recommend both IMC RT and
anthracycline-based chemotherapy sequentially for women with
poor prognostic features, such as nodal involvement.
Strengths of our study include data on RT ﬁelds and type of
chemotherapy, GP- and cardiologist-reported CVD incidence and
cardiovascular risk factors and long and near-complete follow-up.
Surveillance bias in our study population is unlikely, as there are
no recommendations concerning CVD screening in the nation-
wide to BC follow-up guidelines in the Netherlands, which are
adhered to closely.
A potential limitation that we have considered is whether the
increased CVD risk associated with BC treatment might be due to
a less favourable cardiovascular risk proﬁle among women who
received IMC radiation or anthracycline-based chemotherapy and
this in turn might be associated with higher BC stage and lower
socioeconomic status. However, in our relatively young BC cohort
from two cancer centres, BC treatment was not associated with
IMC, CVD risk factor
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Fig. 2 Cumulative risk of cardiovascular diseases in patients
diagnosed during 1987-1999 and aged 50 years or younger at
breast cancer diagnosis, by internal mammary chain irradiation and
cardiovascular disease risk factors (including smoking) at breast
cancer diagnosis. IMC, internal mammary chain; CVD, cardiovascular
disease; CHD, ischemic heart disease; VHD, valvular heart disease; HF,
heart failure. The analyses of ischemic heart disease, valvular heart
disease, and heart failure shown in this ﬁgure include all diagnoses
of cardiovascular disease, e.g. if a patient was diagnosed with
ischemic heart disease and then later with valvular heart disease
then both events are counted. Patients with a speciﬁc cardiovascular
diagnosis before start of time at risk were excluded from analysis
with that speciﬁc diagnosis as endpoint (n=50 for ischemic heart
disease, n=18 for valvular heart disease, and n=36 for heart failure)
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socioeconomic status, cardiovascular history at BC diagnosis or
cardiovascular risk factors. Data on other risk factors for CVD, such
as family history of CVD, body mass index and chronic obstructive
pulmonary disease, were, unfortunately, not collected. However, in
the Netherlands, BC treatment guidelines do not recommend
taking CVD risk factors into account and, accordingly, no
differences in prevalence were observed between the treatment
categories for the CVD risk factors that were collected. Therefore,
missing information on other CVD risk factors is unlikely to have
affected our estimates. Another potential limitation is the
possibility of unreported events. Because, inherent to a retro-
spective study design, we rely on the registration of events in
medical records, it is possible that some CVD events might have
gone unreported. This might have caused our estimates to be
slightly underestimated. Lastly, our study did not include patients
treated with trastuzumab or taxanes, nor were we able to consider
the different types of endocrine therapy. CVD rates after these
modern systemic therapies should be evaluated in future studies.
In conclusion, anthracycline-based chemotherapy and irradia-
tion using regimens with substantial mean heart doses (9–17 Gy)
were associated with increased incidence of several types of CVDs.
The predicted absolute risks of IMC RT are lower for women today,
and for most women, the beneﬁts will exceed the risks. However,
the risks may be greater for some subgroups, e.g. women with
left-sided BC who receive both IMC irradiation and anthracycline-
based chemotherapy or who have cardiovascular risk factors. For
BC survivors, our results are also relevant as subgroups may
beneﬁt from cardiac surveillance.45
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